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Edited by Ivan SadowskiAbstract We have recently reported that poly-SUMO-2/3 con-
jugates are subject to a ubiquitin-dependent proteolytic control in
human cells. Here we show that arsenic trioxide (ATO) increases
SUMO-2/3 modiﬁcation of promyelocytic leukemia (PML)
leading to its subsequent ubiquitylation in vivo. The SUMO-
binding ubiquitin ligase RNF4 mediates this modiﬁcation and
causes disruption of PML nuclear bodies upon treatment with
ATO. Reconstitution of SUMO-dependent ubiquitylation of
PML by RNF4 in vitro and in a yeast trans vivo system revealed
a preference of RNF4 for chain forming SUMOs. Polysumoyla-
tion of PML in response to ATO thus leads to its recognition
and ubiquitylation by RNF4.
 2008 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
Keywords: Small ubiquitin-like modiﬁer; Ubiquitin; Relatively
interesting new gene ﬁnger; Protein degradation;
Promyelocytic leukemia1. Introduction
The role of certain poly-ubiquitin chains as signals for degra-
dation of proteins by the 26S proteasome is well established [1].
While in mammalian cells there are examples where modi-
ﬁcation with small ubiquitin-related modiﬁer isoform 1
(SUMO-1) stabilizes a protein by antagonizing its ubiquityla-
tion [2], recent studies in yeast have established that SUMO
modiﬁcation can also serve as a proteolytic targeting signal that
is recognized by ubiquitin ligases for SUMO conjugates (ULS)
[3–7]. These ULS proteins, which are characterized by a rela-
tively interesting new gene (RING) domain and short SUMO
interaction motifs (SIMs), bind to polysumoylated proteins
and prevent their accumulation. Mutations in yeast ULS genesAbbreviations: ATO, arsenic trioxide; Ni-NTA, nickel-nitrilo triacetic
acid; GSH, glutathione; GST, glutathione S-transferase; His6, 6·His
tag; NB, nuclear body; PML, promyelocytic leukemia; RING,
relatively interesting new gene; RNF4, RING ﬁnger protein 4; SAE,
SUMO activating enzyme; SIM, SUMO interaction motif; SUMO,
small ubiquitin-related modiﬁer; UBC9, SUMO conjugating enzyme;
ULS, ubiquitin ligase for SUMO conjugates
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doi:10.1016/j.febslet.2008.08.008can be complemented by the human ubiquitin ligase RNF4/
SNURF indicating that it is a human ULS [8,4–6]. RNF4 inter-
acts with PML [9] and may thus be involved in a proteolytic
control of PML. Experiments in human cells showed that
mainly high molecular weight conjugates of the nearly identical
chain forming SUMO-2 and SUMO-3 isoforms are subject to a
proteolytic control by the proteasome. In contrast to SUMO-1,
conjugates of SUMO-2/3 isoforms have been shown to be in-
duced by heat, oxidative or osmotic stress [10].
Sumoylation of the human PML protein is necessary for the
formation of PML-NBs (reviewed in [11]). The normal PML
protein as well as the oncogenic fusion protein between PML
and the retinoic acid receptor a (RARa), which causes acute
promyelocytic leukemia (APL), are degraded in response to ar-
senic trioxide (ATO, reviewed in [12]). Under these conditions
sumoylation at lysine 160 precedes degradation [13]. In this
study, we have investigated the mechanism that leads to
PML downregulation in response to ATO treatment. We
demonstrate a direct link between ATO-induced SUMO-2/3
modiﬁcation of PML and its RNF4-mediated and ubiquitin-
dependent degradation by the proteasome.2. Materials and methods
2.1. Stable cell lines inducibly expressing His-tagged SUMO isoforms
SUMO-1, -2 and -3 were cloned with an N-terminal MRGS-His6
epitope into a pCDNA4/TO/myc-His B. T-REx HeLa cells (Invitro-
gen) were grown in EMEM (Gibco), 2 mM glutamine, 1% non-essen-
tial amino acids, 10% fetal bovine serum, 100 U/ml penicillin, 100 lg/
ml streptomycin and 5 lg/ml blasticidin (InvivoGen) and stably trans-
fected with Gene Juice (Novagen). Selection was carried out with
150 lg/ml zeocin (InvivoGen) and individual colonies were subcloned,
expanded and screened for similar induction properties.
2.2. Analysis of SUMO conjugates in stable His6-SUMO expressing
cells
Cells were transiently transfected, after 9 h induced with 1 lg/ml
doxycyclin (Fluka) and 15 h later treated with 1 lMATO (Alfa Aesar)
and/or 20 lM MG132 in DMSO (Biomol) for 6 and 3 h, respectively.
Nickel-nitrilo triacetic acid (Ni-NTA) aﬃnity puriﬁcations were per-
formed with 5 · 106 cells in urea buﬀer as described [6]. In some
experiments, the eluates were used for a subsequent FLAG pull-down.
For direct FLAG pull-downs, whole cell lysates from 5 · 106 cells
were prepared under alkaline conditions and subjected to immunopre-
cipitations as described [6].
2.3. Protein puriﬁcation and in vitro ubiquitylation
SUMO-modiﬁed PML proteins were puriﬁed from an Escherichia
coli in vivo sumoylation system, in which N-terminally glutathioneblished by Elsevier B.V. All rights reserved.
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pressed from pET-Duet1, His6-SUMO-1 or -3 and untagged SUMO
conjugating enzyme (UBC9) from pRSF-Duet1, and human His6-
SAE1 and untagged SAE2 from pACYC-Duet1 (all Novagen).
Expression in BL21 (DE3) cells was induced by 0.1 mM IPTG at
30 C. His6-SUMO-modiﬁed PML was isolated by consecutive gluta-
thione (GSH)-sepharose and Ni-NTA aﬃnity puriﬁcations, TEV pro-
tease cleavage of the GST-tag and gel ﬁltration. Unmodiﬁed PML and
RNF4 were isolated by GSH-sepharose aﬃnity puriﬁcation, TEV
cleavage and gel ﬁltration. RNF4-dependent ubiquitylation reactions
were carried out for 7 h at 30 C in 40 mM Tris/HCl, pH 7.5,
67 mM KCl, 4 mM MgCl2, 5 mM ATP, 200 lg/ml BSA, 2 mM
DTT, 1 lg/ml leupeptin, 1 lg/ml aprotinin, 1 lg/ml pepstatin,
200 lM pefabloc and contained 3 lg/ml UBE1 (Biomol), 3 lg/ml
UBCH5b, 300 lg/ml ubiquitin (Biomol), 100 lg/ml substrate and
30 lg/ml RNF4 where indicated.
2.4. Immunoﬂuorescence and antibodies
Cells were grown on cover slips and ﬁxed in PBS with 3% parafor-
maldehyde. After permeabilization in PBS with 0.1% saponin (Sig-
ma–Aldrich), cells were blocked in PBS, 3% BSA, 0.2% saponin.
Primary and Alexa-labeled secondary antibodies (Invitrogen) were ap-
plied in blocking buﬀer. Cover slips were embedded in ProLong Gold
antifade (Invitrogen) and examined using a Zeiss Axioplan2 ﬂuores-
cence microscope. DsRed-Mito (Clontech) was used as a transfection
control. Proteins and epitope tags were detected with the following
antibodies: SUMO-1: anti-GMP1 (Zymed), SUMO-2/3: ab22654 (Ab-
cam), Smt3: rabbit serum [6], PML: 5E10 [14] and sc-5621 (Santa
Cruz), His-tag: 34650 or 34660 (Qiagen), FLAG: M2 or F7425 (Sig-
ma–Aldrich), HA: 3F10 (Roche), Myc: 9E10 (Sigma–Aldrich), T7:
T7-HRP, 69048 (Merck).
2.5. Experiments in Saccharomyces cerevisiae
The yeast strains JD47-13C (wt) and a 2 lm/LEU2-based plasmid
(pKG87) expressing RNF4 from PCUP1 were described previously
[6]. N-terminally T7-tagged PML 1–522 was expressed from PGAL1 in
a CEN/URA3-based plasmid (pKG117), a derivative of YCplac33
[15]. YKU25-1 is a spontaneous temperature sensitive uba2 derivative
of JD47-13C. The mutation was identiﬁed as a suppressor of ulp2D
(kind gift of K. Uzunova). Cells were grown in synthetic media con-
taining 2% galactose and 100 lM CuSO4. Preparation of extracts
and analysis by immunoblotting and pull-downs of T7-PML from ex-
tracts prepared was performed with T7-resin (Merck) essentially as de-
scribed above for FLAG-tagged proteins.3. Results and discussion
We have recently shown that SUMO-2/3 conjugates are tar-
geted for proteasomal degradation by ubiquitylation [6]. Based
on these data, we suggested that the observed ATO-induced
degradation of PML following its sumoylation may involve
ULS-mediated targeting [13,6]. In order to test this hypothesis,
we ﬁrst analyzed the eﬀect of ATO on the conjugatable SUMO
isoforms in human cells. Similar to osmotic and oxidative
stress [10], ATO resulted in a signiﬁcant increase in SUMO-
2/3 conjugates, which were accumulating to very high levels
upon inhibition of the proteasome (Fig. 1A). SUMO-1 conju-
gates, in contrast, were much less aﬀected by these treatments.
Consistent with previous studies [11], we observed upregula-
tion of modiﬁed endogenous PML in untreated as well as in
interferon-c-treated cells upon treatment with ATO (Fig 1B).
These forms were apparently stabilized upon inhibition of
the proteasome. In order to analyze the modiﬁcation of
sumoylated PML in more detail, we established inducible cell
lines expressing His6-tagged versions of SUMO-1, -2 or -3.
We then transfected these cell lines with a FLAG-tagged trun-
cated version of splice form PML11 (residues 1–522), which
comprises the regulatory regions present in most PML iso-forms and in the PML-RAR-a fusion protein, namely the
TRIM domain, three sumoylation sites and a recently de-
scribed degron around the SIM [16]. Treatment with ATO re-
sulted in the appearance of several distinct higher molecular
weight forms of sumoylated PML between 100 and 170 kDa
in the transfectants coexpressing FLAG-PML 1–522 and
His6-SUMO-2 or -3, but not in the His6-SUMO-1 coexpressing
cells (Fig. 1C and D). Similar results were obtained for FLAG-
tagged full length isoforms 6 and 11 (data not shown). In con-
trast to the situation for endogenous PML, inhibition of the
proteasome in the transfectants had no detectable eﬀect on
modiﬁed FLAG-PML 1–522 (Fig. 1C). Likely reasons are
the high levels of FLAG-PML together with the strong deple-
tion of ubiquitin upon proteasome inhibition (see also
Fig. 1E). The upregulation of SUMO-2/3 modiﬁed forms of
FLAG-tagged PML 1–522 occurred not only after ATO treat-
ment but also upon oxidative and osmotic stress (data not
shown). Together, these results suggested that upregulation
of SUMO-2/3 conjugates and the degradation of PML in re-
sponse to ATO are linked processes. The high molecular
weight forms of His6-SUMO-2/3 conjugated FLAG-PML
were absent in case of the K160R mutant (data not shown),
consistent with the observed resistance of this mutant towards
ATO-dependent degradation [13].
We have previously shown that SUMO-ubiquitin hybrid
conjugates exist in yeast and human cells [6]. Sequential Ni-
NTA and anti-FLAG aﬃnity puriﬁcations from His6-
SUMO-2 expressing cells co-transfected with FLAG-PML 1–
522 and HA-ubiquitin revealed that high molecular weight hy-
brid conjugates of PML occur in vivo upon ATO treatment
(Fig. 1E). This indicates that such conjugates represent inter-
mediates on the way towards proteasomal ATO-induced deg-
radation of PML.
Since PML can be sumoylated in yeast cells [17], we have
tested the eﬀect of the potential human ULS protein RNF4
on levels of SUMO conjugates and on PML (Fig. 2A and
B). Expression of T7-tagged PML 1–522 led to the appearance
of several bands corresponding to unmodiﬁed and yeast
SUMO-conjugated PML (compare anti-T7 and anti-Smt3
blots). The slower migrating bands were absent from a strain
with an impaired SUMO-activating enzyme (uba2-ts) [18]
(Fig. 2B, left panel). We conﬁrmed that these bands represent
sumoylated PML by detection with anti-Smt3 after immuno-
precipitation of T7-PML (Fig. 2B, middle and right panel).
In the presence of RNF4, the slower migrating bands were
diminished indicating that RNF4 targets Smt3/SUMO-modi-
ﬁed PML to degradation in S. cerevisiae. Moreover, the
expression of RNF4 alone decreased the levels of Smt3 conju-
gates of endogenous yeast proteins (Fig. 2A).
In order to directly show that RNF4 mediates a SUMO-
dependent ubiquitylation of PML, we reconstituted this reac-
tion in vitro. To achieve this, we set up reactions using recom-
binant ubiquitin, UBE1, UBCH5b, RNF4 and PML 50–179
produced in E. coli. PML modiﬁed with His6-SUMO-1 or -3
was produced in E. coli cells expressing sumoylation enzymes.
While RNF4 failed to mediate ubiquitylation of unmodiﬁed
PML, we detected an RNF4-dependent ubiquitylation of
PML modiﬁed with SUMO-1 and -3. Both types of SUMO-
modiﬁed PML were ubiquitylated in an RNF4-dependent
manner but His6-SUMO-3 modiﬁed PML was ubiquitylated
more eﬃciently (Fig. 2C). In contrast, ubiquitylation of linear
GST-SUMO-1 or -3 fusion proteins as well as of RNF4 itself
Fig. 1. SUMO-dependent ubiquitylation and degradation of PML induced by ATO. (A) Accumulation of SUMO-2/3 conjugates by ATO and other
stress factors. Whole cell extracts of HeLa cells treated with either 7% ethanol for 20 min, 1 lMATO for 1 h or 100 mMH2O2 for 20 min and with or
without MG132 prior to stress were analyzed by Western blotting against SUMO-1 (left panel) and SUMO-2/3 (right panel). (B) Degradation of
endogenous PML by ATO. Whole cell extracts of untreated (left panel) or interferon-c stimulated HeLa cells (right panel, 200 U/ml, 24 h) were
analyzed by anti-PMLWestern blotting. (C) Accumulation of high molecular weight forms of PML after treatment with ATO. Anti-FLAGWestern
blot of whole cell extracts from stably transfected cells expressing His6-SUMO and transiently transfected with FLAG-PML 1–522 were analyzed by
anti-His Western blotting after treatment with and without ATO and MG132. (D) Stimulation of His6-SUMO-2/3 conjugation of PML by ATO.
Anti-His Western blot of anti-FLAG pull-down from cells after treatment as in C. (E) Formation of hybrid SUMO-ubiquitin conjugates of PML
after ATO treatment. Anti-HA Western blotting of sequential Ni-NTA and anti-FLAG pull-downs from stable His6-SUMO-2 cells transiently
transfected with FLAG-PML 1–522 and HA-ubiquitin after treatment with MG132 or ATO. Anti-FLAG IgG bands are marked with asterisks.
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dence for the speciﬁcity of the reaction (Fig. 2C and Supple-
mentary Fig. 1). The preference of RNF4, which carries
several SIMs, for SUMO-3-modiﬁed PML is likely to be due
to a higher avidity for SUMO chains as we have observed
for the yeast ULS protein Hex3/Slx8 [6].To test whether RNF4 is involved in the degradation of
PML in response to ATO in human cells, myc-tagged RNF4
and FLAG-tagged PML 1–522 were transfected into His6-
SUMO-2 expressing cells and treated with ATO and/or the
proteasome inhibitor MG132 (Fig. 2D). As previously
described, overexpressed RNF4 and PML co-localize in
Fig. 2. The human ULS protein RNF4 targets sumoylated PML. (A) Overexpression of RNF4 reduces the levels of endogenous SMT3/SUMO
conjugates (right panel, in duplicates) and of sumoylated PML in Saccharomyces cerevisiae (left panel, in duplicates). (B) Sumoylation of T7-PML 1–
522 in S. cerevisiae is absent in uba2-ts cells (left panel, in duplicates). Sumoylated forms were detected by anti-Smt3 blotting after pull-down of T7-
PML (right panel). (C) RNF4-dependent ubiquitylation of SUMO-modiﬁed PML in vitro. Unmodiﬁed, His6-SUMO-1- and His6-SUMO-3-modiﬁed
PML 50-179 were generated in Escherichia coli and puriﬁed by liquid chromatography (right panel). RNF4-dependent ubiquitylation was analyzed
by SDS–PAGE followed by anti-His (left panel) and anti-ubiquitin (middle panel) Western blotting. Residual His-tagged TEV protease is marked
with an asterisk. (D) RNF4 and ATO act synergistically in dispersal of PML-NBs. Cells expressing His6-SUMO-2 were transiently transfected and
stained for FLAG-PML 1–522 (blue) and Myc-RNF4 (green) after treatment with ATO and MG132. Mito-DsRed was used as a transfection control
(red). The bottom panel shows a control without transfection of Myc-RNF4.
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creased in size and number. After addition of ATO hardly
any PML-NBs were detectable. When both MG132 and
ATO were added, the cells resembled those not treated witheither compound. ATO treatment of cells overexpressing
PML alone did not lead to PML-NB dispersal.
In summary our data conﬁrm the proposed function
of RNF4 as a ULS protein and identify PML as its ﬁrst
3178 S.R. Weisshaar et al. / FEBS Letters 582 (2008) 3174–3178mammalian substrate. Speciﬁcally, we show that RNF4 medi-
ates a proteolytic control of PML in response to ATO. The
molecular target of ATO, however, is still unknown, as it
may interfere with multiple pathways. We found that ATO
treatment increases the amount of SUMO-2/3 conjugates to
a similar extent as described for stress factors such as oxidative
stress [10], and our in vitro assay demonstrates a preference of
RNF4 for SUMO-3 over SUMO-1 modiﬁed substrates. Thus,
increased conjugation of SUMO-2/3 or an inhibition of its
deconjugation could be suﬃcient to activate RNF4-dependent
degradation of PML. In addition, ATO might trigger signaling
events such as the described phosphorylation of PML, which
has been shown to precede sumoylation and degradation of
PML [19,16]. While this manuscript was in preparation, two
other studies appeared that support our view that RNF4 is a
ULS that mediates proteolytic targeting of sumoylated PML
[20,21].
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